Tenaya Therapeutics granted stock options to purchase 1,650,000 shares to newly appointed CFO Eric Hyllengren and an aggregate of 187,200 shares to two new non-executive employees. The options have an exercise price of $0.8365 per share, equal to the July 13, 2026 closing price, a ten-year term, and vest over four years with a one-year cliff and monthly vesting thereafter. The grants were made under the 2024 Inducement Equity Incentive Plan as an inducement material to employment in accordance with NASDAQ Listing Rule 5635(c)(4).
Tenaya Therapeutics IncGrant of inducement stock options to new CFO and employees; dilutive but aligns incentives, no direct business impact.